Therefore, whether levels of active VWF are truly increased in cirrhosis patients with HCC, and whether increased levels of VWF could have prognostic utility or become an additional therapeutic target, particularly in compensated cirrhosis, should be further explored. This evidence concerns the gene VWF and hepatocellular carcinoma.